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Abstract
A two factor, three level (32) face centered, central composite design (CCD) was applied to 
investigate the main and interaction effects of tablet diameter and compression force (CF) on 
hardness, disintegration time (DT) and porosity of mannitol based orodispersible tablets (ODTs).
Tablet diameters of 10, 13 and 15 mm, and CF of 10, 15 and 20 kN were studied. Results of 20
multiple linear regression analysis show that both the tablet diameter and CF influence tablet 
characteristics. A negative value of regression coefficient for tablet diameter showed an inverse 
relationship with hardness and DT. A positive value of regression coefficient for CF indicated an 
increase in hardness and DT with increasing CF as a result of the decrease in tablet porosity. 
Interestingly, at the larger tablet diameter of 15 mm, while hardness increased and porosity 25
decreased with an increase in CF, the DT was resistant to change. The optimised combination
was a tablet of 15 mm diameter compressed at 15 kN showing a rapid DT of 37.7 s and high 
hardness of 71.4 N. Using these parameters, ODTs containing ibuprofen showed no significant 
change in  DT (ANOVA; p > 0.05) irrespective of the hydrophobicity of the ibuprofen. 
30
KEYWORDS: face centred central composite design, tablet diameter, compression force, 
porosity, hardness, disintegration time 
1.0 Introduction 
The demand for orodispersible tablets (ODTs) has grown over the last decade with the number of 35
commercial over-the-counter and prescription ODT products now reaching over 450 (Aubrey, 
2011). This expansion is attributed to the convenience the ODTs offer to the patient population.
While originally developed for specific patient groups such as the pediatric, geriatric, patients 
with dysphagia as well as travelling patients, ODTs have since gained popularity amongst the 
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wider patient population (Abdelbary et al., 2005). To allow this expansion in ODT application, 40
the number of ODT technologies has increased with a major shift from lyophilisation towards 
conventional tableting. Depending on the process used therefore, the resultant ODTs vary in their 
key properties of disintegration time (DT) and mechanical strength (Fu et al., 2004; Sandri et al., 
2006). In general ODTs produced by lyophilisation tend to have the most rapid DT of 2-3 
seconds due to their high porosity; however these have poor mechanical strength requiring 45
specialised packaging (Corveleyn and Remon, 1997; Seager, 1998). Conventional processing 
produces ODTs with higher mechanical strength but as these are inherently less porous, they 
show slower disintegration. 
Ideally, the ODT should disintegrate rapidly, be pleasant tasting and of sufficient mechanical 50
strength to withstand handling, packaging, transport and more importantly should be easy to 
handle by the patient (Okuda et al., 2009). It is interesting that European Pharmacopoeia (PhEur, 
2008) describes an ODT as a tablet which disperses readily and within 3 minutes before 
swallowing while according to the FDA (FDA, 2008); ODTs should have an in vitro DT of 30
seconds or less. 55
Considerable efforts have been applied to modify conventional tableting formulation and/or the 
process in order to produce ODTs with rapid DT while maintaining sufficient mechanical 
strength. Wehling and Schuehle, 1996; Wehling et al., 1993 report the addition of effervescent 
excipients and use of low compression force to increase the disintegration rate of ODTs. 60
However, they report that the resultant ODTs had a low mechanical strength requiring 
specialised packaging. To improve mechanical strength of these ODTs, other researchers have 
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subjected directly compressed tablets to post compaction treatment. Various post compaction 
treatment used include exposure to humidity and/or heat, to effect a solid state transition of 
amorphous sugars (such as maltose) to its crystalline form (Mizumoto et al., 2005) or heating to 65
attain phase transition of sugar alcohols such as xylitol (Kuno et al., 2005; Kuno et al., 2008). 
Mizumoto et al., 2005 reported an increase in the hardness by approximately 4-fold to 4 kp,
without causing any change in the DT at 10-15 s, whereas Kuno et al., 2005 reported that after 
12 hours treatment, an approximately 4.5-fold increase in the hardness to 4.5 kp and a 5-fold 
increase in the DT to about 30 s was observed.70
Compression force (CF) is known to affect tablet properties and in general an increase in CF 
results in an increase in tablet hardness and is accompanied by an increase in DT. Bi et al., 1999
reported that for 8 mm tablets, a 5-fold increase in the CF to 4.9 kN caused approximately an 11-
fold increase in the tensile strength to 23 kg/cm2 and a 2.4-fold increase in DT of tablets to 31 s. 75
The increase in CF resulted in a decrease in tablet porosity to 16%. Similarly for tablets of 
diameter 10 mm, Schiermeier and Schmidt, 2002 reported an approximately 5-fold increase in 
the tablet crushing strength to 71 N when the CF was increased by 2.5 times to 10 kN. The 
authors reported a corresponding increase in the DT and tablet wetting time. Late et al., 2009
reported that an increase in tablet hardness resulted in an increase in the DT of tablets of 11 mm 80
diameter. 
Studies of the impact of CF on tablet hardness, porosity and DT for the ODTs have been carried 
out predominantly for tablet of diameters in the range of 8 – 11 mm. Tablets of these diameters 
are generally applicable to a limited weight and dose range. A larger tablet diameter of 25 mm85
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was studied by Schiermeier and Schmidt, 2002. The authors reported that a 2-fold increase in CF 
caused approximately a 5-fold increase in the tablet crushing strength to 130 N, and a 2-fold 
increase in DT to 78 seconds. Commercially available ODT tablets have diameters ranging from 
9 mm to 17.5 mm and at the larger diameters of13 mm and greater, they can accommodate 
higher drug dosage of 100mg (El-Arini and Clas, 2002; Klancke, 2003; McLaughlin et al., 90
2009) (Table 1). 
Tablet diameters have also been reported to influence the characteristics of tablets. Kiekens et 
al., 2004 reported a decrease in tablet tensile strength from 3.99 to 3.68 MPa when the tablet 
diameter increased from 4 mm to 9.5 mm whereas, Rawas-Qalaji et al., 2007 reported a non-95
significant increase in hardness from 6.8  0.4 to 7.2  0.3 kg for directly compressed tablets 
when tablet diameter increased from 7.94 mm to 8.73 mm. DT of the tablets was found to be ≤ 
10 seconds.
In the present study the influence of increasing compressional force and tablet diameter on the 100
mechanical strength, porosity and DT of tablets prepared by direct compression was examined. 
A two factor, three level (32) face centered, central composite design (CCD) was used and 
response surface methodology was applied to determine the interaction of compression force and 
tablet diameter for ODT formulations with optimal hardness and DT. Statistical models with 
interaction terms were derived to investigate the relative significance of the two variables, tablet 105
diameter (X1) and compression force (X2) and their interaction on the responses i.e. hardness 
(Y1), disintegration time (Y2) and porosity of tablets (Y3). The water soluble sugar-alcohol, 
mannitol was used as the filler in combination with sodium starch glycollate (SSG) and calcium 
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silicate (CS) as disintegrants. The two disintegrants were chosen for their complimentary 
mechanism of disintegration to optimise disintegration process. CS was added for its capillary 110
action (Pabari and Ramtoola, 2012) in order to maximize uptake of the disintegration medium 
into the tablet and swelling of SSG and hence facilitating disintegration of the tablet. The 
optimum parameters of tablet diameter and compression force were applied to formulate ODTs 
containing ibuprofen at increasing content to a pediatric dose of 50 mg. Ibuprofen is a non 
steroidal anti-inflammatory drug (NSAID) widely used in both adults and children for the 115
treatment of analgesia and pyrexia. Pediatric doses of ibuprofen at 100 mg and below are 
available commercially as oral liquid preparations (100 mg/5 ml) and more recently as an oral 
ODT preparation at 100 mg dose. A low dose of ibuprofen at 50 mg formulated as an ODT 
would represent a convenient alternative dose form.
120
2.0 Materials and Methods 
2.1 Experimental design 
The face centered, central composite design contains an imbedded factorial design with center 
points. It is used to find the best set of values, for a set of factors, giving an optimal response. In 
this mathematical approach the design helps in exploring quadratic surface responses where each 125
experimental response (Y) can be represented (Late and Banga, 2010). A polynomial model 
developed based on the regression analysis of the statistically significant variables enables the 
study of the effects of each factor (X) and their interaction over the considered responses (Y) and 
hence can be used to predict responses of hardness (Y1), disintegration time (Y2) and porosity 
(Y3) values for orodispersible tablets. Comparison of predicted values for Y1, Y2 and Y3 with 130
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experimental data was used to test validity of the models. The independent factors, their levels 
and the analysed dependent responses are shown in Table 2.
The matrix of the face-centered central composite design (CCD) is outlined in Table 3. Each row 
in the matrix represents an experiment and each experiment presents a set of results, which 135
include the 3 responses or dependant variables studied. The selected levels are within practical 
use and were chosen to have a measurable effect on the responses. For the purpose of CCD, 13 
mm was taken as 12.5 mm, the centre point for the tablet diameters of 10 mm and 15 mm. The 
statistical experimental design was generated, evaluated for the quality of fit of the model and the 
constant and regression coefficients were calculated using the Design-Expert® software (Version 140
8.0.1 Stat-Ease Inc. Minneapolis, USA)  
2.2 Materials 
Mannitol 200 was a gift from Parteck®, Merck KGaA; Norman Lauder, Dublin, calcium silicate
(RxCIPIENTSTM FM1000) was a gift from Huber engineered, Finland, sodium starch glycollate145
(Explotab®) was a gift from JRS Pharma, Germany. Magnesium stearate was a gift from JMB, 
UK. 
2.3 Formulation of orodispersible tablets (ODTs) 
Mannitol 200 and the disintegrants were weighed and blended together for 5 minutes in a 150
resealable plastic bag. The disintegrants, calcium silicate and sodium starch glycollate, were 
added at 10% w/w. Magnesium stearate at 0.5 %w/w was added to the sugar and disintegrant 
blend and blended gently for 1-2 minutes. Tablets were compressed at a compression force 
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ranging 10-20 kN and speed of 7 rpm using an 8 Station rotary tablet press (Riva Piccola, 
Hampshire, UK) fitted with flat faced bevelled edge (FBE) tools of diameter 10-15 mm as 155
described by Ramtoola et al., 2008. Tablets were compressed to a target weight of 300 or 500 mg
+/- 10% depending on the tablet diameter. To limit the effect of compression force on varying 
volumes/heights of powder to be compressed, a lower weight of powder of 300mg was selected 
for the 10mm tablet diameter. Powder weight (w) is directly proportional to volume (v) of the 
powder to be compressed and volume is defined by v=r2/h where r=tablet radius and h is the 160
height of powder to be compressed. The height of powder to be compressed is therefore 
proportional to r2/v or r2/w. At 500mg weight, this ratio would range from 0.2 to 0.45 for 10-
15mm diameters respectively which is a 2 fold difference in height. To keep the height (or r2/w) 
in a narrow range, a lower weight of 300mg for the 10mm diameter was used to give a height (or 
r2/w) in the range of 0.33 to 0.45 for 10-15 mm diameters respectively.165
2.4 Characterisation of tablets
2.4.1 Uniformity of weight (mass) and thickness 
Uniformity of tablet weight was carried on n=5 tablets, taken randomly and weighed individually 
on a Sartorius balance, Model CP225D, Bradford, MA, USA. The average weight of the tablets 170
+/- standard deviation was calculated. The thickness of each ODT (n=5) was measured using a 
pair of calibrated digital Vernier callipers (Digital Caliper Workzone, UK).
2.4.2 Mechanical strength of tablets
Hardness or crushing strength of the tablets was carried out individually on n=5 tablets using a 175
pre-calibrated PTB 411E Tablet hardness tester (PharmaTest Germany). The average hardness 
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+/- standard deviation was calculated. The tensile strength (tentile) which takes into account 
dimensions of the compact, was calculated from the measured hardness/crushing strength 
(Ffailure), using equation 1 (Heinz et al., 2000): 
180
                                                                       (1)
For beveled edge flat faced tablets, 
Across-sectional area = 2 x (cup area) + 2rh
Where,185
r = radius of tablet,
h = height of tablet edge
Cup area was provided by Natoli Engineering Company, Inc, Missouri, USA
2.4.3 Friability test 190
Friability test on tablets was performed on n=10 tablets using a pre-calibrated PTFE Friability 
tester, (PharmaTest Germany). If tablets cracked, cleaved, or broke after testing, the sample was 
recorded as ‘Failed’ for failed friability test. 
2.4.4 Disintegration test 195
The disintegration tests were performed using deionised water maintained at a temperature 
between 37˚C ± 2˚C, using a pre-calibrated Pharmatest PTZ Auto, PTFE Disintegration tester, 
(PharmaTest Germany). Only one ODT at a time was placed into the disintegration apparatus 
σtensile = 
areationedcross
failure
A
F
sec.
.2

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and the time taken (seconds; s) for the tablet to fully disintegrate was recorded. The test was 
repeated with 4 additional ODTs and the average DT +/- standard deviation were calculated. 200
2.4.5 Porosity of tablets 
The porosity of the tablets () was calculated using equation 2 (Sugimoto et al., 2005), 
 = (
v
m
true
1 ) x 100                                               (2)
Where, true = true density of the tableting mixture, m = weight of the tablet, v = volume of the 205
tablet. 
The true density of the materials was determined using helium pycnometer, (Accupyc 1330, 
V3.03, Micrometrics, Norcross, USA) and is given by:
v= 2 x (cup volume) + r2h 
Where,210
r = radius of tablet
h = height of tablet edge
cup volume as provided by Natoli Engineering Company, Inc, Missouri, USA
2.5 Statistical analysis 215
The results obtained are expressed as a mean ± standard deviation calculated using Microsoft 
excel (Redmond, WA, USA) software. Statistical analysis was performed using SPSS version 
15.0 for windows (SPSS, Inc, Chicago, IL, USA). One-way ANOVA followed by the Tukey
multiple comparisons were used to compare the results. A p value of less than 0.05 was 
considered as statistically significant.220
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3.0 Results and discussion 
Tablet weight showed very low variability of less than 1% as was expected from the excellent 
flow of the direct compression grade mannitol used (Table 4). The tablet thickness also showed 
low variability related to the formulation flow and consistency of compression force. A decrease 225
in tablet thickness was observed with increasing compression force (CF) at each tablet diameter 
studied, signifying an increase in tablet density. The low variability observed for both parameters 
support the reproducibility of the formulation and tableting process used for the study. The 
responses, hardness, DT and porosity are presented in Table 4.
3.1 Statistical analysis and mathematical modeling of experimental data230
The values for the responses hardness (Y1), disintegration time (Y2), and porosity (Y3) of the 
ODTs were analysed using the Design-Expert® software and the mathematical model for each 
response was generated. Results of the multiple linear regression analysis for each response 
variable derived by the best fit method are shown in equations 3-5 below. 
235
Y1 (Hardness) = +457.91286 - 81.12971 * X1 + 9.78295 * X2 + 0.077600 * X1 * X2 
   + 3.14423 * X12 - 0.18194 * X22 (3)
Y2 (DT) = -25.11369 -11.68062 * X1 +25.41755 * X2 -1.27260 * X1 * X2 
+0.85577 * X12 -0.19926 * X22 (4)240
Y3 (Porosity) =  +14.87367 +1.56467*X1-0.70267* X2 (5)
Page 13 of 29
Ac
ce
pte
d M
an
us
cri
pt
12
Equations 3 - 5 reflect the quantitative influence of process variables; X1 (tablet diameter) and 
X2 (compression force (CF)) and their interactions on the responses; Y1 (hardness), Y2245
(disintegration time), and Y3 (porosity). 
Analysis of variance (ANOVA) for the responses indicated that the quadratic regression model 
was significant and valid for each of the responses Y1 (p = 0.0008) and Y2 (p = 0.0003) and 
hence was appropriate to represent the observed data for hardness and DT, respectively. For the 
response Y3, linear regression model was significant (p < 0.0001). The statistical analysis for the 250
response surface quadratic/linear model showed the standard error of estimate was 2.51 for Y1, 
2.11 for Y2 and 0.42 for Y3. 
From the regression equations 3, 4 and 5, both factors, X1 (tablet diameter) and X2 (CF)
influence the hardness (Y1), disintegration time (Y2) and porosity (Y3) of the tablets. The 
negative regression coefficient of variable X1 in equation 3 and 4 suggest a decrease in hardness 255
and disintegration time (DT) with an increase in tablet diameter, while a positive regression 
coefficient of variable X1 in equation 5 suggest an increase in porosity with an increase in tablet 
diameter. A positive sign was observed for regression coefficient X2 (CF) in equation 3 and 4, 
and a negative sign for X2 was observed in equation 5, showing that an increase in CF results in 
an increase in hardness and DT and a decrease in porosity.260
In equations 3 and 4, factors at higher order (i.e. X22) denote quadratic relationships, while 
coefficient containing both factors, (i.e. X1X2) indicates an interaction effect of factors studied 
on the responses. The positive regression coefficient for the quadratic term X12 in equation 3 and 
4 indicate that the hardness (Y1) and DT (Y2) decreased with increasing tablet diameter to a 265
minimum after which it increased, whereas a negative sign observed for the quadratic term X22
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indicates that as CF increased, both hardness and DT increased to a maximum, after which it 
decreased. The interaction of tablet diameter (X1) and compression force (X2) had a positive 
impact on the hardness (Y1) but a negative impact on the disintegration time (Y2) as observed by 
the respective coefficients in equations 3 and 4, respectively.  270
Quality of fit of the model for each response was carried out. The R2 values for the observed 
responses were 0.97, 0.98 for Y1 and Y2 respectively. Corresponding linear regression analysis 
gave an r2 value of 0.91 for Y3. Corresponding “Predicted R2 or Q2” values for responses Y1, Y2 
and Y3 were 0.85, 0.92 and 0.83 respectively. Hence the model was found statistically excellent 275
for all three responses of Y1, Y2 and Y3. 
The relationship between the dependent variables hardness (Y1), disintegrating time (Y2) and 
porosity (Y3) and the independent variables tablet diameter (X1) and CF (X2) is demonstrated 
on the surface response plots in Fig. 1a-c. The plots also show the region of maxima (region in 280
red) and minima (region in blue) for each of the 3 responses investigated.
3.2 Analysis of the fitted data – Hardness (Y1) and Porosity (Y3)
The response surface plot for the effect of tablet diameter (X1) and CF (X2) and their interaction 
effects on the hardness of orodispersible tablets (ODT) (Y1) and porosity (Y3) is illustrated in 285
Fig. 1a and c. An increase in the tablet diameter from 10 mm to 15 mm resulted in a significant 
decrease in the tablet hardness from 45 to 37 N at 10 kN (ANOVA; post hoc, p < 0.002). This 
was related to the 2-fold decrease in the CF per unit surface area, from 0.127 to 0.062 kN/mm2. 
A 2-fold increase in the compression force from 10 to 20 kN led to a 2.2-fold increase in tablet 
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hardness to 100 N for 10 mm tablets and about 2.5-fold increase in hardness at the larger 290
diameter of 15 mm. Schiermeier and Schmidt, 2002 reported a 5-fold increase in the crushing 
strength to 71 N for a 2.5-fold increase in CF to 10 kN for 10 mm orodispersible tablets. Fig. 1a 
also illustrates the quadratic relationship of effect of tablet diameter on tablet hardness. An 
increase in tablet diameter resulted in a decrease in hardness to a minimum after which hardness 
increased.295
Fig. 1c shows the linear relationship of effect of compression force and tablet diameter on tablet 
porosity. Compression decreases the intermolecular voids resulting in densification, inter-particle 
bonding to enhanced binding and densification of tablets (Van Veen et al., 2000). Both enhanced 
binding and densification results in increased tablet hardness and tensile strength. This 
relationship in our experiments is shown in Fig. 2 which describes the linear relation between the 300
tensile strength and porosity of tablets at all diameters studied, r2 values of 1.0, 0.94 and 0.94 for 
10, 13 and 15 mm tablets, respectively. The ODTs at all the tablet diameters passed the friability 
test showing a percent weight loss of less than 1%.
3.3 Analysis of the fitted data – disintegration time (Y2) and porosity (Y3)305
The response surface plot for effect of tablet diameter and CF on disintegration time (Y2) of 
ODTs is illustrated in Fig. 1b. The DT (Y2) of the tablets was found to be inversely proportional 
to the tablet diameter (X1). An increase in tablet diameter from 10 mm to 15 mm  resulted in a 
significant decrease in the DT from 49 to 37 s at CF of 10 kN (ANOVA; post hoc, p < 0.004). At 
the higher CF of 20 kN, increasing tablet diameter showed a larger decrease in DT from 117 to 310
42 s for a diameter increase from 10 to 15 mm. Increasing tablet diameter resulted in an increase 
in tablet porosity (Y3) as a result of the reduction in applied CF per unit surface area. An 
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increase in porosity of tablets generally facilitates the rate of water uptake into the tablet core 
resulting in faster tablet wetting and disintegration time. The decrease in DT with increasing 
tablet diameter is demonstrated in Fig. 3 a- c.   315
At constant diameter, an increase in CF (X2) by 2-fold to 20 kN caused a significant increase in 
DT (Y2) from 49 to 117 s for 10 mm tablets (ANOVA, post hoc, p < 0.0001). Schiermeier and 
Schmidt, 2002 reported a 1.6-fold increase in the wetting time of 10 mm tablets to 23.7 s when 
CF was increased from 4 to 10 kN. Interestingly in our study, at 15 mm tablet diameter, a 2-fold 
increase in the CF did not result in a significant increase in DT (ANOVA, post hoc, p > 0.05), 320
despite a decrease in tablet porosity. This occurrence can be related to the larger surface of the 15 
mm tablets which facilitates wetting and disintegration when in contact with the disintegration 
medium.
3.4 Validation of the model 325
Theoretical (predicted) values of Y1 (hardness), Y2 (disintegration time) and Y3 (porosity) for 
the 9 experiments were calculated from the response surface models; equations 3, 4 and 5
respectively, by substituting values of X1 (tablet diameter) and X2 (compression force). Good 
correlation between theoretical (predicted) values and the observed (actual) values were 
observed for responses Y1 (hardness), Y2 (disintegration time) and Y3 (porosity) (Table 5).330
In order to validate the model, the center points i.e. 13 mm was compressed at two compression 
force not selected for the central composite design i.e. at 12 kN and 18 kN. At 12 kN, the actual 
hardness, DT and porosity values were found to be 34.6 ± 5.0 N, 50.3 ± 2.5 s and 26.1% 
respectively, which were in close agreement with the values predicted by the model of 37.9 N, 
47.3 s and 26% respectively. Similarly, at 18 kN, the actual hardness, DT and porosity values 335
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measured were 68.4 ± 4.7 N, 63.7 ± 3.1 s and 23.2% and were in close agreement with the model 
predicted values of 69.7 N, 69.2 s and 21.8%, respectively.
The response surface optimization was carried out to derive the optimum combination of tablet 
diameter (X1) and compression force (X2) to formulate tablets with hardness (Y1) greater than 340
40 N and DT (Y2) of below 40 s. The combination of tablet diameter of 15 mm compressed at 15 
kN was found to give a desirability value of 1, showing a high hardness of 71.4 N and rapid 
disintegration time of 37.7 s. Reformulation using these parameter  resulted in ODTs of 
reproducible hardness and DT values of 65.1 ± 7.1 N and 39.3 ± 2.9 s respectively.
345
3.5 Application of the optimum process parameters to formulate paediatric Ibuprofen ODT
The optimum tableting process parameters of 15 mm and 15 kN was used to formulate ODTs 
containing increasing dose of ibuprofen from 10 to 50 mg. A decrease in tablet hardness was 
observed with increasing ibuprofen content (Fig. 4) although this decrease in hardness was not 
statistically significant at the low ibuprofen content of 10 mg. No significant change in the DT 350
was observed regardless of the ibuprofen concentration (ANOVA; p > 0.05) (Fig. 4). The 
characteristics of small diameter tablets have been reported to be influenced by the addition of 
actives. Hydrophobic actives generally tend to decrease tablet disintegration time. Yang et al., 
2004 reported a large increase in DT by 8.8-fold to 219.5 s when the tablet content of ketoprofen 
was increased from 0 to 100 mg although no significant increase in the tensile strength was 355
observed. In contrast Rawas-Qalaji et al., 2006 reported that increasing the epinephrine bitartrate 
content of tablets of diameter of 8.73 mm from 0 to 36 mg caused a 6-fold decrease in hardness 
to 2 kg and a 7-fold decrease in DT to 5.6 s was observed. Epinephrine bitartrate is hydrophilic
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while ketoprofen is hydrophobic and the change in the tablet properties reported was related to 
the physicochemical properties of the active. In our study, ibuprofen is hydrophobic with a 360
higher log P value compared with ketoprofen and therefore the decrease in hardness may be a 
result of decrease in bonding due the higher hydrophobic nature of ibuprofen.  
4.0 Conclusions
In this study compression force and tablet diameter were observed to have a profound and 365
interactive effect on the characteristics of orodispersible tablets as shown by the models obtained 
using a central composite design and response surface methodology. The data observed showed 
this experimental design was successfully applied to optimise the combination of tablet diameter 
and compression force to formulate ODTs with desirable properties of high mechanical strength 
and low DT. The optimised combination in this study was a tablet diameter of 15 mm 370
compressed at 15 kN. Using this combination of process variables, ODTs formulated were 
resistant to a change in the DT despite an increase in hardness. The optimised process parameters 
were successfully applied to formulate rapid disintegrating and mechanically strong ODTs at 
increasing dose of the analgesic non-steroidal anti-inflammatory agent Ibuprofen. These process 
combinations may have wider application to other actives to achieve ODTs with desirable 375
qualities of rapid disintegration and high mechanical strength.  
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Fig. 1. Response surface plot showing the effect of X1 (tablet diameter) and X2 (compression 
force) on (a) Y1 (hardness of ODT), (b) Y2 (disintegration time of ODT), (c) Y3 (porosity of 
ODT) (the region in red is the maxima while the region in blue is the minima)
460
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Fig. 2. Correlation of tablet tensile strength (N/cm2) and tablet porosity (%) of ODTs of 
increasing tablet diameters
465
470
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Fig. 3. Disintegration profile of ODT of increasing tablet diameters (a) 10 mm, (b) 13 mm and
(c) 15 mm
480
485
Fig. 4. Influence of increasing ibuprofen content on the hardness and disintegration time of 
ODTs formulated using the optimized tablet diameter of 15 mm and compression force of 15 kN490
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Table 1:  Commercially available orally disintegrating tablets 
Tab510
le 2:
Vari
able
s in 
32515
cent
ral 
com
posit
e520
desi
gn 
Levels usedIndependent variable, Factor
Low (-1) Middle (0) High (1)
X1; Table diameter (mm) 10 13 15
X2; Compression force (kN) 10 15 20
Dependent variable, response 
Y1 = hardness (N) 
Y2 = disintegration time (s)
Y3 = porosity (%)
525
Table 3 Matrix of 32 central composite design 
Exp. No Tablet diameter
(X1)
Compression force (X2)
Name Tablet 
diameter 
Active and dosage 
strength
Process DT
Zofran Zydis® 9 mm 4mg,8mg Ondansetron Lyophilisation 2.2 s
AlavertTM
(CIMA)
10 mm 10mg Loratadine Direct compression 32.8 s
Xilopar Zydis® 11 mm 1.25mg Selegiline Lyophilisation 2.8 s
Elan 13.0 mm 100mg Nimesulide Wet granulation/ 
Compression
25 s
Calpol®fastmelts
Flashtab® 
14.3 mm 250mg Paracetamol/
808.2 mg 
Dry granulation/
compression
< 60 s
Nurofen® 
Meltlets
15 mm 200mg Ibuprofen Dry granulation/
compression
31 s
Excedrin®
QuicktabsTM
17.5 mm 500mg Acetaminophen Dry granulation/
Comparession
25.8 s
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1 -1 0
2 0 1
3 1 -1
4 1 1
5 -1 -1
6 0 0
7 0 -1
8 1 0
9 -1 1
530
535
540
545
Table 4 Characteristics of orodispersible tablets Data expressed as mean +/- SD (n = 3)
 1Friability (% weight loss)
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Table 5 Theroetical (predicted) values and the observed ( ctual) values observed for responses 550
Y1 (hardness) and Y2 (disintegration time) 
/ Y1 (Hardness – N) Y2 (DT - s) Y3 (Porosity - %)
Exp Predict Act Resid Predict Act Resid Predict Act Resid
1 78.5 80.3 1.8 89.2 91.3 2.1 20.0 18.8 -1.2
2 77.4 73.5 -3.8 73.1 70.7 -2.4 20.4 21.6 1.2
3 39.7 37.5 -2.2 35.6 37.3 1.7 31.3 30.0 -1.3
4 94.6 97.0 2.4 39.1 42.0 2.9 24.3 24.1 -0.2
5 48.4 45.2 -3.2 50.7 49.0 -1.7 23.5 25.0 1.5
6 55.4 54.7 -0.8 60.4 61.7 1.3 23.9 25.0 1.1
7 24.4 29.8 5.4 37.8 37.7 -0.10 27.4 26.6 -0.8
8 71.7 71.4 -0.3 42.3 37.7 -4.7 27.8 28.0 0.2
9 99.4 100.9 1.4 117.8 117.3 -0.5 16.5 14.9 -1.6
Exp. 
No
Diameter
(X1)
CF
(X2)
Weight
(mg)
Thickness 
(mm)
Hardness 
(N)
Friab1
(%)
DT (s)
1 -1 0 298.4 ± 3.5 3.06± 0.04 80.3± 3.3 0.00 91.3 ± 3.5
2 0 1 492.1 ± 2.9 3.15± 0.01 73.5± 5.3 0.00 70.7 ± 7.0
3 1 -1 551.1 ± 4.8 2.78± 0.03 37.5± 1.2 0.00 37.3 ± 3.8
4 1 1 541.9 ± 1.8 2.52± 0.02 97.0± 6.9 0.00 42.0 ± 8.9
5 -1 -1 301.3 ± 2.7 3.33± 0.01 45.2± 2.5 0.17 49.0 ± 2.7
6 0 0 495.8 ± 3.8 3.31± 0.06 54.7± 2.6 0.00 61.7 ± 5.0
7 0 -1 490.4 ± 3.3 3.34± 0.04 29.8± 0.8 0.36 37.7 ± 2.1
8 1 0 546.7 ± 0.5 2.68± 0.03 71.4± 10 0.00 37.7 ± 3.8
9 -1 1 293.5 ± 0.7 2.88± 0.03 100.9± 1.7 0.00 117.3 ± 2.1
